Artificial reconstituted pulmonary surfactant in prevention and treatment of respiratory distress syndrome in neonates
Abstract
AIM: To test an artificial reconstituted pulmonary surfactant (APS) for
prevention and treatment of respiratory distress syndrome (RDS).
METHODS: A membrane-formed method combined with supersonic dispersing was used to
prepare APS. A pulsating bubble surface tension measurement was established to
compare surface properties of APS with natural pulmonary surfactant (NPS). A
preliminary clinical trial was made for prevention and treatment of RDS.
RESULTS: The APS reduced surface tension from 44.0 mN/m to < 1.0 mN/m in vitro.
The changes of APS lipid contents were < 5% of labeled content at 37 degrees C.
Clinical trial showed that the APS prevented RDS in 20/20 and cured RDS in 2/2
premature neonates.
CONCLUSION: The APS had good surface properties similar to NPS.
Keywords:
prevention and treatment of respiratory distress syndrome (RDS).
METHODS: A membrane-formed method combined with supersonic dispersing was used to
prepare APS. A pulsating bubble surface tension measurement was established to
compare surface properties of APS with natural pulmonary surfactant (NPS). A
preliminary clinical trial was made for prevention and treatment of RDS.
RESULTS: The APS reduced surface tension from 44.0 mN/m to < 1.0 mN/m in vitro.
The changes of APS lipid contents were < 5% of labeled content at 37 degrees C.
Clinical trial showed that the APS prevented RDS in 20/20 and cured RDS in 2/2
premature neonates.
CONCLUSION: The APS had good surface properties similar to NPS.